16 September 2026 editorial review · Item
Concept: compact dual-hormone patch with stable glucagon: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Concept: compact dual-hormone patch with stable glucagon
Scope and findings:
- Read Q2 2026 SEC filing: first integrated feasibility trial Q4 2025 and additional trial Q1 2026; further excipient and dosing-algorithm improvements identified. Supports early research, not pivotal readiness. Historical dasiglucagon and successor Xeris formulation distinguished; no new trial date established.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.